Pancreatic Cancer Treatment Market Set to Surge from USD 2.9 Billion in 2023 to USD 10.2 Billion by 2034

The global pancreatic cancer treatment market was valued at US$ 2.9 Bn in 2023 and is projected to reach US$ 10.2 Bn by 2034, expanding at a CAGR of 12.4% from 2024 to 2034. The market is being driven by the rising incidence of pancreatic cancer, increasing adoption of advanced diagnostic and treatment technologies, and continued research into targeted and personalized therapeutic approaches.

Growing investments in oncology research are encouraging the development of innovative treatment modalities, including immunotherapies, targeted therapies, advanced radiation techniques, and emerging drug-delivery technologies. At the same time, collaborations between pharmaceutical companies, biotechnology firms, healthcare providers, and research institutions are supporting the development of more precise and effective approaches to pancreatic cancer management.

Transform Your Strategy: Explore In-Depth Data – Sample Available! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86342

Analyst Viewpoint

The increasing incidence of pancreatic cancer remains a major factor supporting the expansion of the global pancreatic cancer treatment market. Because the disease is frequently diagnosed at an advanced stage and can progress rapidly, there is a strong need for earlier diagnosis and more effective treatment options.

Technological progress across oncology is also reshaping the treatment landscape. Healthcare providers are increasingly adopting advanced radiation technologies, improved diagnostic techniques, and novel therapeutic approaches to enhance treatment precision. Meanwhile, companies are collaborating with researchers to investigate genetic and molecular mechanisms associated with pancreatic cancer, creating opportunities for targeted and personalized therapies.

Pancreatic Cancer Treatment Market Overview

Pancreatic cancer originates in the pancreas, an organ located behind the lower portion of the stomach that plays an important role in digestion and blood-sugar regulation. The disease develops when abnormal pancreatic cells grow and divide uncontrollably, eventually forming a tumor.

Pancreatic cancer is particularly challenging to manage because it is often detected at a later stage. Symptoms such as unexplained weight loss, reduced appetite, abdominal discomfort, and other systemic changes may emerge only after the disease has progressed. Consequently, improving diagnostic capabilities and expanding access to effective treatment modalities remain important priorities for healthcare systems.

Treatment approaches include surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, and targeted therapy, depending on the type and stage of the disease. However, adverse effects associated with certain treatments can create challenges for patients and healthcare providers. Chemotherapy, for example, may cause vomiting, fever, pain, dizziness, and other complications, while radiation therapy can be associated with diarrhea, urinary problems, shortness of breath, and changes in taste. Such treatment-related limitations may restrain market growth in some settings.

Key Market Growth Drivers

Rising Incidence of Pancreatic Cancer

The increasing prevalence of pancreatic cancer is creating sustained demand for therapeutic solutions. According to data cited in the market analysis, France recorded 14,461 new pancreatic cancer cases in 2020, while Germany registered approximately 21,859 new cases in 2021. The growing disease burden is encouraging healthcare systems to strengthen screening, diagnosis, treatment, and patient-management capabilities.

Government-supported cancer initiatives are also helping improve access to treatment. For instance, the National Cancer Screening Program in South Korea provides cancer screening to individuals above 50 years of age at minimal or no cost, supporting early detection and broader cancer-management efforts.

Increasing Adoption of Advanced Diagnostic & Treatment Technologies

Advances in diagnostic and therapeutic technologies are strengthening the pancreatic cancer treatment ecosystem. Exocrine pancreatic cancer represents the majority of diagnosed pancreatic cancers, with data cited from the European Society for Medical Oncology indicating that approximately 95% of diagnosed pancreatic cancers are exocrine.

Advanced radiation technologies are increasingly being integrated into cancer treatment centers. In August 2022, Apollo Proton Cancer Centre entered into an agreement with Ion Beam Applications (IBA) to provide proton-based radiation therapy training for clinicians. Earlier, in August 2021, Manipal Hospitals introduced an advanced Radixact System equipped with Synchrony Automatic, Real-time Motion Synchronization Technology for enhanced treatment precision.

Continued technological advancement is therefore expected to support the adoption of sophisticated treatment modalities and contribute to market expansion.

Growing Focus on Innovative Therapeutics

Pharmaceutical and biotechnology companies are investing in novel approaches designed to improve outcomes for patients with pancreatic cancer. Emerging therapies and drug-delivery technologies are expanding the potential treatment landscape beyond conventional chemotherapy and radiation.

In January 2024, the U.S. FDA approved an investigational new drug application for ACT-IOP-003, an implantable iontophoretic product being developed for potential treatment of pancreatic cancer. Its Phase 1b trial was scheduled to begin in mid-2024, highlighting ongoing efforts to explore alternative therapeutic approaches.

Regional Analysis of Pancreatic Cancer Treatment Market

North America to Maintain Market Leadership

North America held the largest share of the global pancreatic cancer treatment market in 2023, and the region is expected to maintain its leading position throughout the forecast period.

The region benefits from advanced healthcare infrastructure, strong oncology research capabilities, high healthcare expenditure, and a favorable regulatory environment. Increasing regulatory approvals for innovative therapies are also contributing to the development of the regional market.

In February 2024, Ipsen announced that it had received approval from the U.S. FDA for a supplemental new drug application for Onivyde, in combination with oxaliplatin, leucovorin, and fluorouracil, as a first-line treatment for adults with metastatic pancreatic adenocarcinoma.

Europe Supported by Expanding Oncology Research

Europe represents another important market for pancreatic cancer treatment, supported by increasing R&D activities and initiatives focused on improving cancer awareness and patient care. Countries including Spain, Italy, France, and Germany are contributing to regional research and treatment development.

For instance, in November 2021, Servier Hellas Pharmaceutique Ltd. organized an event at the French Embassy to increase awareness regarding pancreatic cancer, reflecting the broader emphasis on disease education and awareness across the region.

Analysis of Key Players

The competitive landscape of the pancreatic cancer treatment market includes major pharmaceutical companies, biotechnology firms, and healthcare-focused organizations. Leading participants are pursuing both organic and inorganic growth strategies, including product development, clinical research, strategic collaborations, and expansion of therapeutic portfolios.

In September 2021, F. Hoffmann-La Roche Ltd. entered into a partnership with NovoCure to develop Tumor Treating Fields (TTFields) in combination with the anti-PD-L1 therapy atezolizumab for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Companies are also increasing investments in clinical research and novel treatment approaches to address the significant unmet medical needs associated with pancreatic cancer.

Key companies profiled in the market include:

• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Zydus Cadila
• Myriad Genetics Inc.
• F. Hoffmann-La Roche AG
• PharmaCyte Biotech, Inc.
• Teva Pharmaceutical Industries Ltd.

These companies are analyzed based on company overview, business strategies, financial performance, product portfolio, business segments, geographic presence, subsidiaries or distributors, and recent developments.

Key Player Strategies

Development of Next-generation Cancer Therapies

Market participants are investing in innovative therapeutic approaches aimed at improving treatment efficacy and addressing limitations associated with conventional therapies. Targeted treatments, immunotherapies, advanced radiation technologies, and novel drug-delivery mechanisms remain important areas of development.

Strategic Research Collaborations

Partnerships between pharmaceutical companies, biotechnology firms, research institutions, and healthcare organizations are enabling companies to combine scientific expertise and accelerate development of promising therapies.

Expansion of Clinical Research

Clinical trials continue to play a central role in the competitive landscape as companies evaluate new treatment combinations and technologies for pancreatic cancer. These activities are expected to create opportunities for differentiated products and expand the treatment pipeline.

Competitive Landscape of Pancreatic Cancer Treatment Industry

• In February 2024, the U.S. FDA granted Fast Track designation to IMM-1-104 for the treatment of pancreatic cancer.
• In January 2022, Novartis AG received Orphan Drug Designation (ODD) from the U.S. FDA for NIS793, which is being evaluated in combination with other chemotherapy drugs for pancreatic cancer and other tumors.
• In September 2021, F. Hoffmann-La Roche Ltd. partnered with NovoCure to investigate Tumor Treating Fields in combination with atezolizumab for metastatic pancreatic ductal adenocarcinoma.

Market Challenges & Opportunities

Challenges

Treatment-related Side Effects: Adverse effects associated with chemotherapy and radiation therapy can affect patient quality of life and may influence treatment adherence.

Late-stage Diagnosis: Pancreatic cancer is frequently identified after the disease has progressed, creating significant challenges for effective intervention and limiting treatment options in advanced cases.

Complexity of Disease Management: The aggressive nature of pancreatic cancer and the heterogeneity of tumors create challenges in developing universally effective treatment strategies.

Opportunities

Advanced Targeted & Precision Therapies: Growing understanding of the molecular and genetic mechanisms underlying pancreatic cancer is creating opportunities for targeted and personalized treatment approaches.

Innovative Drug Delivery Technologies: Implantable and localized drug-delivery systems may offer opportunities to improve therapeutic precision while potentially reducing systemic exposure.

Expansion of Immunotherapy & Combination Treatments: Research into immunotherapy and combinations involving existing cancer treatments could broaden the therapeutic landscape and create new avenues for market growth.

Global Pancreatic Cancer Treatment Market Snapshot

Format: Electronic (PDF) + Excel

Market Segmentation

By Treatment Type

• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Surgery
• Radiation Therapy
• Targeted Therapy

By Indication Type

• Exocrine
• Endocrine

By End-user

• Hospitals
• Oncology Clinics
• Others (Research Institutes, etc.)

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Countries Covered

• U.S.
• Canada
• Germany
• U.K.
• France
• Italy
• Spain
• China
• India
• Japan
• Australia & New Zealand
• Brazil
• Mexico
• South Africa
• GCC

Companies Profiled

• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Zydus Cadila
• Myriad Genetics Inc.
• F. Hoffmann-La Roche AG
• PharmaCyte Biotech, Inc.
• Teva Pharmaceutical Industries Ltd.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=86342<ype=S

Frequently Asked Questions

What was the size of the global pancreatic cancer treatment market in 2023?

The global pancreatic cancer treatment market was valued at US$ 2.9 Bn in 2023.

What is the projected size of the pancreatic cancer treatment market by 2034?

The market is projected to reach US$ 10.2 Bn by the end of 2034.

What is the expected CAGR of the pancreatic cancer treatment market?

The global pancreatic cancer treatment market is expected to expand at a CAGR of 12.4% from 2024 to 2034.

What are the major factors driving the pancreatic cancer treatment market?

The primary growth factors include the rising incidence of pancreatic cancer, increasing adoption of advanced diagnostic and treatment technologies, and continued development of innovative cancer therapies.

Which region is expected to dominate the pancreatic cancer treatment market during the forecast period?

North America is expected to maintain its leading position in the global pancreatic cancer treatment market during the forecast period, supported by advanced healthcare infrastructure, technological development, and increasing regulatory approvals for innovative therapies.

What are the major treatment types covered in the pancreatic cancer treatment market?

The market covers chemotherapy, immunotherapy, hormone therapy, surgery, radiation therapy, and targeted therapy.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com